Trevi Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning, and welcome to Needham's 22nd Annual Healthcare Conference. I'm Serge Belanger, one of the senior healthcare analysts at Needham. And happy to have our next session, the Trevi Therapeutics team. We have CEO, Jennifer Good; CFO, Lisa Delfini; and the new Chief Medical Officer, David Clark. (Conference Instructions)
So Jennifer, I'll hand it over to you for just a quick overview.
Sounds great, Serge. Thank you for having us. We're appreciative of our partnership with Needham. Trevi came off a big year in 2022. I'm one of the two co-founders.
So we've been on a journey, proving out the mechanism of the drug, that I presume we'll talk more about in the fireside chat. We had two key programs going on, one within a severe pruritus condition called prurigo nodularis; and the other was an exploratory program in cough in idiopathic pulmonary fibrosis, which has been quite difficult and there have been some
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |